Objective This study aims to analyze the current status of pneumococcal vaccines(PV)in the National Immunization Program(NIP)among the 194 member countries of the World Health Organization(WHO)and provide scientific evidence for optimizing and adjusting China's PV immunization strategy.Methods Public data on PV immunization programs,vaccine types,and vaccination rates of target populations were collected from 194 member states in the six WHO regions,and descriptive analysis was performed.Results Among the 194 WHO member countries,163 countries have included at least one type of PV in their NIP for children,adults,or high-risk populations,156 countries have included PV in their NIP for children,40 countries in the high-risk population NIP,and 28 countries in the adult NIP.Among the three main PV used globally,the 10-valent pneumococcal conjugate vaccine(PCV)has been included in the NIP of 39 countries,the 13-valent PCV has been included in the NIP of 133 countries,and the 23-valent pneumococcal polysaccharide vaccine(PPV)has been included in the NIP of 44 countries.Regarding the 10-valent PCV immunization program for children,147 countries adopted the 3-dose schedule,17 countries adopted the 4-dose schedule,and two countries adopted the 2-dose schedule.The 3-dose PCV coverage has increased from 4.19％in 2008 to 50.82％in 2021.Conclusions Based on the inclusion of PV in the NIP,vaccination schedules,and coverage in 163 out of 194 WHO member countries,the health administration in our country should carefully consider the burden of pneumococcal diseases,PV coverage,cost-effectiveness,and vaccine supply.It is recommended that we expedite the process of including PV in our NIP,especially incorporating PV into the childhood NIP.
Pneumococcal vaccineWorld Health Organization(WHO)National Immunization ProgramCoverageVaccination schedule
NETL
NSTL
万方数据
